araag2/HINT huggingface dataset:
Clinical trial NCT00118729 (phase 3, status: completed)
Conditions: rhinitis, allergic, seasonal
ICD codes: J30.2
Drugs: gw685698x aqueous nasal spray
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion criteria:

          -  Informed consent

          -  Outpatient

          -  Females must use appropriate contraception

          -  Diagnosis of seasonal allergic rhinitis

          -  Able to comply with study procedures

          -  Literate

        Exclusion criteria:

          -  Significant concomitant medical condition

          -  Use of corticosteroids, allergy medications, or tobacco

          -  Clinically significant abnormal ECG

          -  Laboratory abnormality

          -  Positive pregnancy test

          -  Allergy to any component of investigational product
Clinical trial NCT00210730 (phase 3, status: terminated)
Conditions: anemia
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Reason stopped: 
    this study was stopped early due to slow enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of non-myeloid malignancy

          -  Baseline hemoglobin value >= 11 g/dL and <= 12 g/dL unrelated to transfusion

          -  Female patients with reproductive potential must have a negative serum pregnancy test
             at screening. Patients must have signed an informed consent

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  History (within 6 months) of uncontrolled cardiac arrhythmias, or history of pulmonary
             emboli, deep vein thrombosis, ischemic stroke, other arterial or venous thrombotic
             events (excluding superficial thromboses), or known history of chronic coagulation
             disorder

          -  Transfusion within 28 days prior to first dose

          -  Planned myelosuppressive chemotherapy or radiation during study and no prior
             chemotherapy within 8 weeks or radiation within 4 weeks of study entry.
Clinical trial NCT00396877 (phase 3, status: completed)
Conditions: heart defects, congenital
ICD codes: Q76.3, D70.0, D74.0, H55.01, P37.0, P37.1, P83.5
Drugs: clopidogrel (sr25990), placebo
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Cyanotic congenital heart disease treated by any palliative systemic-to-pulmonary
             artery shunt.

        Exclusion Criteria:

          -  Active bleeding or increase risk of bleeding,

          -  Allergy to 2 or more classes of drug,

          -  Unable to receive drug orally or enterically,

          -  Current clinically significant or persistent thrombocytopenia, neutropenia, severe
             hepatic or renal failure.
Clinical trial NCT00048581 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept, placebo, abatacept
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Eligibility criteria:

        Eligibility Criteria:

          -  Active rheumatoid arthritis currently failing anti-TNF therapy or have failed anti-TNF
             therapy in the past.

        Exclusion Criteria:

          -  Women who are pregnant or breast feeding

          -  Current symptoms of serious medical disease

          -  History of cancer in last 5 years other than non-melanoma skin cancer

          -  Chronic serious infection

          -  Active TB requiring treatment in last 5 years

          -  Herpes zoster in last 2 months

          -  Any active viral infection including Human Immunodeficiency Virus (HIV)

          -  Serious side effects associated with previous anti-TNF therapy
Clinical trial NCT00106535 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: tocilizumab [roactemra/actemra], placebo, methotrexate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients at least 18 years of age with moderate to severe active RA for at least
             6 months;

          -  inadequate response to a stable dose of MTX;

          -  patients of reproductive potential must be using reliable methods of contraception.

        Exclusion Criteria:

          -  major surgery (including joint surgery) within 8 weeks before entering study, or
             planned surgery within 6 months after entering study;

          -  prior treatment failure with an anti-tumor necrosis factor agent;

          -  women who are pregnant or breast-feeding.
Clinical trial NCT01237496 (phase 3, status: completed)
Conditions: hepatitis b, chronic
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: peginterferon alfa-2a [pegasys]
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients 18-55 years of age

          -  Chronic HBeAg negative hepatitis B

          -  Liver disease consistent with chronic hepatitis documented by liver biopsy within 18
             months prior to enrollment

          -  Participation in study ML18253.

        Exclusion Criteria:

          -  Interferon-based or any systemic anti-HBV therapy </= 12 months prior to first dose of
             study drug

          -  Antiviral, anti-neoplastic, or immunomodulatory treatment </= 12 months prior to first
             dose of study drug

          -  Nonresponders to previous interferon therapy and resistant to lamivudine

          -  Co-infection with hepatitis A, C or D, or with human immunodeficiency virus (HIV)

          -  Hepatocellular cancer

          -  Compensated (Child A, score 6) or decompensated liver disease (Child B or C)

          -  History or evidence of medical condition associated with chronic liver disease other
             than HBV
Clinical trial NCT00679588 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: semuloparin sodium, enoxaparin sodium, placebo
SMILES: \N, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient undergoing major abdominal surgery (open surgery under general anesthesia
             lasting more than 45 minutes in the peritoneal and/or retroperitoneal space and/or
             pelvis).

          -  Patient <60 years of age had to have one of the following additional risk factors for
             VTE:

               -  History of VTE,

               -  Obesity,

               -  Chronic Heart failure,

               -  Chronic Respiratory Failure,

               -  Inflammatory Bowel Disease,

               -  Cancer Surgery.

        Exclusion Criteria:

          -  Any major orthopedic or general surgery in the 3 months prior to study start;

          -  Clinical signs or symptoms of DVT or PE within the last 12 months or known post
             phlebitic syndrome;

          -  Any contra-indications to the performance of venography;

          -  High risk of bleeding;

          -  Known hypersensitivity to heparin or Enoxaparin sodium;

          -  End stage renal disease or patient on dialysis.

        The above information was not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
Clinical trial NCT01041404 (phase 3, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: trastuzumab, fluorouracil, cisplatin, capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients >=18 years of age

          -  Inoperable locally advanced, recurrent, and/or metastatic cancer of the stomach or
             gastro-esophageal junction

          -  Adenocarcinoma

          -  HER2-positive tumors

        Exclusion Criteria:

          -  Previous chemotherapy for advanced/metastatic disease

          -  Lack of physical integrity of the upper gastrointestinal tract, or malabsorption
             syndrome

          -  History of cardiac disease

          -  Dyspnoea at rest, due to complications of advanced malignancy or other disease, or
             patients who require supportive oxygen therapy
Clinical trial NCT00251004 (phase 3, status: completed)
Conditions: kidney transplantation, graft rejection
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0, T86.830, T86.820
Drugs: everolimus, mycophenolic acid (mpa), cyclosporine a (csa), basiliximab, corticosteroids
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients of any race between 18 to 70 years old (inclusive)

          -  Patients who gave written informed consent to participate in the study

        Exclusion Criteria:

          -  Recipients of multi-organ transplantation

          -  Recipients of a primary cadaveric or primary non-human leucocyte antigen (HLA)
             identical living donor kidney transplantation.

          -  Graft cold ischemia time greater than 40 hours.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00170690 (phase 3, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: treosulfan, treosulfan
SMILES: CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O, CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  patient with relapsed ovarian cancer

          -  study therapy of third regime

          -  measurable or evaluable tumor lesions or progression defined as CA-125 more than >=
             100 U/ ml.

          -  Age >= 70 years

          -  ECOG 0-2

          -  written informed consent

        Exclusion Criteria:

          -  Pretreatment with treosulfan

          -  patient without measurable or evaluable tumor lesions or CA-125 more than >= 100 U/
             ml.

          -  no adequate bone marrow function (leukocyte <= 2,9 x 109/l, platelets <= 100 x 109/ l

          -  creatinin and bilirubin within >= 1,25 x fold of the reference laboratory´s normal
             range

          -  simultaneous radiotherapy
Clinical trial NCT02694536 (phase 3, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: erlotinib, gemcitabine
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma with locally advanced,
             unresectable, or metastatic disease

          -  No prior systemic treatment for metastatic disease

          -  Adjuvant therapy ≥6 months prior to study entry with no residual toxic effects

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3

          -  Life expectancy ≥12 weeks

          -  Adequate hematologic, hepatic, and renal function

          -  Negative pregnancy test within 72 hours of study drug and use of effective
             contraception among women of childbearing potential

        Exclusion Criteria:

          -  Unstable systemic disease

          -  Prior systemic human epidermal growth factor receptor 1 (HER1) or epidermal growth
             factor receptor (EGFR) inhibitors

          -  Other malignancy within 5 years prior to study entry

          -  Significant opthalmologic abnormality

          -  Inability to take oral medication

          -  Need for IV alimentation

          -  Prior surgery affecting absorption

          -  Active peptic ulcer disease

          -  Nursing mothers
Clinical trial NCT00356447 (phase 3, status: completed)
Conditions: vasomotor symptoms
ICD codes: J30.0
Drugs: estradiol/drsp (angeliq, bay86-4891), placebo
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Chinese postmenopausal women with moderate to severe vasomotor symptoms

        Exclusion Criteria:

          -  History of steroid hormone dependent malignant disease

          -  Known or suspected malignant or premalignant disease

          -  Current or history of severe heart, liver, renal, psychiatric disease

          -  Hyperlipemia
Clinical trial NCT00541658 (phase 3, status: completed)
Conditions: postmenopausal osteoporosis
ICD codes: N95.0, N95.2
Drugs: risedronate, risedronate, risedronate
SMILES: OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O, OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O, OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female: 50 years of age or older

          -  >5 years since last menses natural or surgical

          -  have lumbar spine or total hip BMD more that 2.5 SD below the young adult mean, or
             have lumbar spine or total hip BMD more than 2.0 SD below the young adult female mean
             value and also have at least one prevalent vertebral body fracture

        Exclusion Criteria:

          -  history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia

          -  BMI >32 kg/m

          -  use of medications within 3 months of starting study drug that impact bone metabolism
             such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and
             parathyroid hormone

          -  hypocalcemia or hypercalcemia of any cause

          -  markedly abnormal clinical laboratory measurements that are assessed as clinically
             significant by the investigator
Clinical trial NCT01048242 (phase 3, status: completed)
Conditions: insomnia, obstructive sleep apnea
ICD codes: F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, A81.83, G47.33
Drugs: rozerem, placebo
SMILES: CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Obstructive sleep apnea

          -  Insomnia

          -  Age>60

        Exclusion Criteria:

          -  Cognitive impairment

          -  Active alcohol or substance abuse

          -  Active use of other sedative-hypnotic agents

          -  Active use of fluvoxamine (drug interaction with Ramelteon

          -  Evidence of hepatic dysfunction (Ramelteon contraindicated) on liver function panel

          -  Presence of Periodic Limb Movement Disorder or Restless Legs Syndrome

          -  Severe Chronic Obstructive Pulmonary Disease
Clinical trial NCT00120003 (phase 3, status: completed)
Conditions: stroke
ICD codes: G46.4, G46.3, Z82.3
Drugs: candesartan cilexetil, placebo
SMILES: CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical stroke syndrome with limb paresis, not likely to represent a transient
             ischaemic attack or non-stroke pathology (e.g. cerebral tumour)

          -  Systolic blood pressure ≥ 140 mm Hg

          -  Trial treatment possible within 30 hrs of symptom onset. If time of onset is not
             known, use the time when the patient was last known to be well.

          -  Consent (subsidiary, assent from legal acceptable representative, or waiver of
             consent)

          -  Age >18 years

        Exclusion Criteria:

          -  Markedly reduced consciousness (i.e. Scandinavian Stroke Scale consciousness score ≤
             2)

          -  Patient already receiving AT1 receptor blocker

          -  Contraindication to treatment with AT1 receptor blocker, e.g.:

               -  known renal failure (women: creatinine ≥ 150 µmol/L; men: ≥ 180 µmol/L)

               -  previously diagnosed bilateral renal artery stenosis

               -  previously diagnosed high-grade aortic stenosis

               -  previously diagnosed seriously impaired liver function and/or cholestasis

               -  known intolerance to candesartan or other tablet ingredients

          -  Clear indication, in the clinician's view, for start of treatment with AT1 receptor
             blocker during the treatment period (e.g. chronic heart failure grade III-IV, in the
             presence of intolerance to ACE inhibitors)

          -  Clear indication, in the clinician's view, for antihypertensive therapy during the
             acute phase of stroke (i.e. concurrent hypertensive encephalopathy or aortic
             dissection, or other situations)

          -  Other serious or life-threatening disease before the stroke:

          -  Patient severely mentally or physically disabled (e.g. Mini Mental Status score < 20,
             or modified Rankin Scale score ≥ 4)

          -  Life expectancy < 12 months

          -  Patient unavailable for follow-up (e.g. no fixed address)

          -  Pregnant or breast-feeding woman
Clinical trial NCT00284856 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: montelukast sodium, comparator: placebo, comparator: fluticasone, comparator: placebo
SMILES: [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN(C)C(=N)NC(N)=N, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with chronic asthma who actively smoke at least 0.5 to no more than 2
             packs of cigarettes a day

        Exclusion Criteria:

          -  Participant cannot have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or
             emphysema.
Clinical trial NCT00529451 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: aliskiren, ramipril
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have msDBP ≥ 90 mmHg and < 110 mmHg at the visit immediately prior to
             Visit 3

          -  Patients must have msDBP >OR= 95 mmHg and < 110 mmHg at Visit 3

          -  Patients must have an absolute difference of < or =10 mmHg in their mean sitting
             diastolic blood pressure (msDBP) from Visit 2 to Visit 3

        Exclusion Criteria:

          -  Severe hypertension (grade 3 WHO classification; msDBP >or= 110 mmHg and/or msSBP >or
             = 180 mmHg).

          -  History or evidence of a secondary form of hypertension.

          -  History of transient ischemic cerebral attack within 12 months of visit 1.

          -  Current angina pectoris requiring pharmacological therapy (other than those patients
             on a stable dose of oral or topical nitrates)

          -  Type 1 or Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) > 8% at Visit
             1.

          -  Known or suspected contraindications to the study medications, including history of
             allergy to ramipril or other ACE Inhibitors.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00123487 (phase 3, status: completed)
Conditions: myeloid leukemia, chronic, accelerated phase, leukemia, lymphoblastic, acute, philadelphia-positive
ICD codes: C83.57, C83.50, C91.01, C91.02, C83.52, C83.56, C83.53
Drugs: dasatinib, dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Patients with Philadelphia-Positive (Ph+) (or BCR/ABL+) accelerated phase chronic
             myeloid leukemia, Ph+ (or BCR/ABL+) blast phase chronic myeloid leukemia, or Ph+ (or
             BCR/ABL+) acute lymphoblastic leukemia whose disease has primary or acquired
             hematologic resistance to imatinib mesylate or who are intolerant of imatinib mesylate

          -  Men and women, 18 years of age or older

          -  Adequate hepatic function

          -  Adequate renal function

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for a period of at least 1
             month before and at least 3 months after the study in such a manner that the risk of
             pregnancy is minimized

          -  Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  A serious uncontrolled medical disorder or active infection that would impair the
             ability of the subject to receive protocol therapy

          -  Uncontrolled or significant cardiovascular disease

          -  Medications that increase bleeding risk

          -  Medications that change heart rhythms

          -  Dementia or altered mental status that would prohibit the understanding or rendering
             of informed consent

          -  History of significant bleeding disorder unrelated to CML

          -  Concurrent incurable malignancy other than CML

          -  Evidence of organ dysfunction or digestive dysfunction that would prevent
             administration of study therapy

          -  Prior therapy with BMS-35425

          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must
             not be enrolled into this study